Gilde Healthcare Cooperatieve Sells 1,181,131 Shares of LAVA Therapeutics (NASDAQ:LVTX) Stock

LAVA Therapeutics N.V. (NASDAQ:LVTX) major shareholder Gilde Healthcare Cooperatieve sold 1,181,131 shares of the stock in a transaction dated Friday, October 17th. The shares were sold at an average price of $1.47, for a total transaction of $1,736,262.57. Following the completion of the transaction, the insider owned 2,947,781 shares of the company’s stock, valued at $4,333,238.07. This represents a 28.61% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Gilde Healthcare Cooperatieve also recently made the following trade(s):

• On Thursday, October 16th, Gilde Healthcare Cooperatieve sold 690,239 shares of LAVA Therapeutics stock. The shares were sold at an average price of $1.49, for a total transaction of $1,028,456.11.
• On Tuesday, October 14th, Gilde Healthcare Cooperatieve sold 227,341 shares of LAVA Therapeutics stock. The shares were sold at an average price of $1.51, for a total transaction of $343,284.91.
• On Monday, October 13th, Gilde Healthcare Cooperatieve sold 47,686 shares of LAVA Therapeutics stock. The shares were sold at an average price of $1.54, for a total transaction of $73,436.44.
• On Friday, October 10th, Gilde Healthcare Cooperatieve sold 49,869 shares of LAVA Therapeutics stock. The shares were sold at an average price of $1.55, for a total transaction of $77,296.95.
• On Thursday, October 9th, Gilde Healthcare Cooperatieve sold 48,169 shares of LAVA Therapeutics stock. The shares were sold at an average price of $1.56, for a total transaction of $75,143.64.
• On Wednesday, October 8th, Gilde Healthcare Cooperatieve sold 28,954 shares of LAVA Therapeutics stock. The shares were sold at an average price of $1.57, for a total transaction of $45,457.78.

LAVA Therapeutics Stock Down 1.3%

Shares of LVTX opened at $1.47 on Wednesday. The firm has a 50-day moving average price of $1.55 and a 200 day moving average price of $1.40. The firm has a market capitalization of $38.68 million, a PE ratio of -1.40 and a beta of 0.50. LAVA Therapeutics N.V. has a 52-week low of $0.85 and a 52-week high of $2.09.

LAVA Therapeutics (NASDAQ:LVTX) last announced its earnings results on Wednesday, August 13th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.04). On average, equities analysts expect that LAVA Therapeutics N.V. will post -1.13 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of LAVA Therapeutics in a report on Wednesday, October 8th. Jefferies Financial Group downgraded shares of LAVA Therapeutics from a “buy” rating to a “hold” rating and cut their price target for the company from $3.00 to $1.50 in a report on Tuesday, August 5th. Finally, HC Wainwright cut their price target on shares of LAVA Therapeutics from $1.50 to $1.24 and set a “neutral” rating for the company in a report on Tuesday, August 5th. Six research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Reduce” and an average price target of $2.69.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. BML Capital Management LLC purchased a new position in shares of LAVA Therapeutics in the first quarter worth approximately $2,490,000. XTX Topco Ltd purchased a new position in shares of LAVA Therapeutics in the first quarter worth approximately $31,000. Lepercq De Neuflize Asset Management LLC purchased a new position in shares of LAVA Therapeutics in the first quarter worth approximately $29,000. Finally, Rangeley Capital LLC purchased a new position in shares of LAVA Therapeutics in the second quarter worth approximately $36,000.

About LAVA Therapeutics

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.